您的当前位置:首页 > 行业数据 > II期临床:氘可来昔替尼vs安慰剂16周ACR-20缓解率
图片属性
图片格式:PNG 图片大小:50KB 图片尺寸:1112*816
同报告图片
 / 4
II期临床:氘可来昔替尼vs安慰剂16周ACR-20缓解率_第1页
fCDoja/nianlj4rliYLph48gfCBBQ1ItMjDnvJPop6PnjocgKCUpIHwKfC0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwKfCDmsKLlj6/mnaXmmJTmm7/lsLw2bWcgcWQgKE49NzApIHwgNTAgfAp8IOawouWPr+adpeaYlOabv+WwvDEybWcgcWQgKE49NjcpIHwgNjAgfAp8IOWuieaFsOWJgiAoTj02NikgfCAzMCB8CgrotYTmlpnmnaXmupDvvJpBbm4gUmhldW0gRGlzLiAyMDIyOzgxKDYpOjgxNS04MjLvvIzljY7ms7DnoJTnqbY=
II期临床:氘可来昔替尼vs安慰剂16周ACR-20缓解率_第2页
II期临床:氘可来昔替尼vs安慰剂16周ACR-20缓解率_第3页
II期临床:氘可来昔替尼vs安慰剂16周ACR-20缓解率_第4页
5qC55o2u5Zu+54mH5Lit55qE5pWw5o2u77yM5Lul5LiL5piv6KGo5qC877yaCgp8IOeWvueXheexu+WIqyAgICAgICAgICAgfCDmr5TkvosgKCUpIHwKfC0tLS0tLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS18Cnwg5YW25LuW55a+55eFICAgICAgICAgICB8IDgxICAgICAgIHwKfCDogr/nmKQgICAgICAgICAgICAgICB8IDkgICAgICAgIHwKfCDkuK3mnqLnpZ7nu4/ns7vnu5/nlr7nl4UgICB8IDEwICAgICAgIHwKCui1hOaWmeadpea6kO+8mkdCRO+8jOWNjuazsOeglOeptg==
II期临床:氘可来昔替尼vs安慰剂16周ACR-20缓解率_第5页
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
所属报告: 翰森制药-港股公司研究报告-创新蕴豪情龙头迎初昕-241229(111页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠